France (FR)

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression (2026) Wahnschaffe L, Jungherz D, Müller TA, Pemovska T, Pichler A, Poulain S, Julia E, et al. Journal article Preferences, attitudes and views regarding genetic newborn screening (gNBS) for rare diseases: a systematic review of the literature and synthesis from 2009 to 2022 (2026) Martin S, Kyosovska-Peshtenska G, Audi J, Zarakowska K, Grauman Å, Veldwijk J, Hauber B, et al. Journal article, Review article Real-time monitoring of multimode squeezing (2026) Kalash M, Sudharsanam A, M. Passos MH, Parigi V, Chekhova M Journal article From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy (2026) Roy N, Liu H, Horenberg AL, Pathak AP, Chen J, Ramasamy SK, Cohen-Solal M, et al. Journal article, Review article Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article Hierarchical supervision in DINOv2 training improves generalizability on white blood cell images (2026) Chossegros M, Wagner S, Matek C, Stockholm D, Tannier X, Marr C Journal article Paired transcriptomics of glioblastoma peripheral and core areas reveals CNTN2 as a potential therapeutic target (2026) Larroquette M, Sarnow K, Meloni M, Rudewicz J, Dartigues B, Epinette E, Guyon J, et al. Journal article Age and provenance constraints for the geodynamic evolution of the Indus Suture Zone during the Cenozoic (2026) Vimpere L, Bouilhol P, Sternai P, Popescu SM, Suc JP, Gorican S, Poujol M, et al. Journal article Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review (2026) Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, et al. Journal article